What is fetal hemoglobin?
Fetal hemoglobin (HbF) is the most dominant form of hemoglobin (Hb) in fetuses and persists until birth, at which time the production of adult Hb is upregulated. Both fetal and adult Hb contain alpha () globin chains; however, in adult Hb, the gamma () globin chains are replaced with beta () globin.
Image Credit: Phonlamai Photo / Shutterstock.com
Six months after birth, HbA is the dominant form of Hb, and any conditions which affect Hb become clinically apparent. At six months, HbF comprises less than 5% of the total Hb, and it continues to fall, reaching the adult level of less than 1% by the age of 2.
The switch from fetal to adult Hb production does not occur to completion, nor is it irreversible. All adults retain the capacity to produce some HbF, which steadily declines throughout adult life. The degree to which HbF persists tends to vary greatly between adults, and this variability is under genetic control.
The persistence of relatively high levels of HbF production is not clinically harmful in healthy individuals; however, in patients suffering from conditions that affect the quality of HbA (such as those suffering from sickle cell disease or -thalassemia), the condition can offer an advantage.
High HbF levels confer significant benefits namely milder disease progression and fewer complications. Therefore, HbF has an ameliorating effect, which has prompted several approaches to therapeutic agent production in patients with mutations affecting adult HbA quality. These approaches include, for example, the pharmacological and gene transfer for HbF synthesis reactivation.
The residual HbF in adults is distributed unevenly amongst the red blood cells; cells that contain measurable quantities are referred to as F cells (FC). These typically contain a mean cell volume (MCV) of between 80-90 fl, compared to larger fetal cells with an MCV of approximately 125 fl. Within the FC, HbF only comprises a small portion of the total Hb.
Detection of FC occurs traditionally by an acid illusion method developed by Kleihauer; however, a much more sensitive immunofluorescence-based method uses an anti- globin antibody for use on fixed red blood cell smears, or via fluorescence-activated cell sorting (FACS), following labeling of the intracellular HbF.
Surveys of healthy blood donors across population groups demonstrate that levels of FC and HbF can vary more than 20-fold, and the distribution is both continuous and positively skewed. Furthermore, family studies show levels of HbF tend to be heritable, although the inheritance patterns are not clear. Twin studies show that the correlation between HbF and FC is genetically controlled, with a heritability of 0.89.
Hereditary persistence of fetal hemoglobin is a condition in which levels of HbF persist at levels greater than typically expected (less than 1%). In hereditary persistence of fetal hemoglobin (HPFH), this HbF percentage varies from levels as low as 0.8-1.0% to approximately 30% of the total hemoglobin.
However, the percentage of HbF can climb as high as 100% in homozygotes (individuals with two copies of the affected gene) for delta beta () thalassemia, another form of thalassemia characterized by defective mutations in the chains of hemoglobin.
This condition is inherited in a mendelian fashion and is caused either by large deletions in the gene that controls the subunit for HbA or by point mutations in the promoter (site of gene expression) of the globin genes. The condition is both benign and asymptomatic. The condition is classified as either pancellular / homocellular or heterocellular, based on the hemoglobin distribution pattern.
Pancellular conditions affect all cells, whereas heterocellular conditions affect some cells, and homocellular conditions affect similar groups of cells. In heterocellular HPFH, the level of HBF can range from 10 to 40%. On the other hand, the levels of HbF in heterocellular HPFH are only modestly elevated, and levels of hemoglobin are unevenly distributed amongst the red blood cells.
Pathogenic increases in HbF, which are distributed heterogeneously, are associated with drug use, malignancies, and hemoglobinopathies. Drugs such as hydroxyurea and pomalidomide increase HPFH. Trisomy 13, a chromosome disorder, is associated with a switch from HbF to HbA with persistently elevated HbF quantities in the blood.
Some patients with -thalassemia, which is caused by reduced or absent synthesis of the globin chains of hemoglobin which reduces the oxygen-carrying capacity of red blood cells, contain elevated levels of HbF that correlate with the degree of chain deficiency as well as a co-inheritance of thalassemia.
This protects against the deleterious effect of - globin chain precipitation, caused by decreased cell: cell chain ratios, which result in unstable tetramers, which are poor carriers of O2.
Other conditions in which elevated HbF is seen in patients include leukemia, following chemotherapy, as well as in patients treated for severe iron deficiency anemia due to acute blood loss. This occurs as a result of 'stressed' hematopoiesis or erythropoiesis (hemoglobin or red blood cell production, respectively). Patients with inherited bone marrow failure syndromes additionally show altered HbF as part of stressed synthesis blood components.
The benefits of HPFH are most noticeable when it co-exists with sickle cell or thalassemia. These conditions cause diminished oxygen-carrying capacity of red blood cells due to unstable chains that form part of the tetramer of the oxygen-binding hemoglobin. As a result, the production of HbF alleviates this issue, as HbF contains rather than chains, which are affected in adult Hb.
Owing to its ability to alleviate the severity of hemoglobinopathies in thalassemias, hereditary persistence of fetal hemoglobin tends to be selected for in populations in which these disorders are prevalent, such as people of African and Greek descent.
Friedman S, Schwartz. Hereditary persistence of foetal haemoglobin with beta-chain synthesis in cis position (gamma-beta+-HPFH) in a negro family". Nature. 1976 doi:10.1038/259138a0
Patel, S. et al. Inheritance of Hereditary Persistence of Fetal Haemoglobin (HPFH) in a Family of Western Odisha, India. J Clin Diagn Res. 2015. doi: 10.7860/JCDR/2015/12878.6548
Sokolova, A. et al. Hereditary persistence of hemoglobin F is protective against red cell sickling. A case report and brief review. Hematology/Oncology and Stem Cell Therapy. doi: 10.1016/j.hemonc.2017.09.003
Collins, F.S. et al. gamma beta+ hereditary persistence of fetal hemoglobin: cosmid cloning and identification of a specific mutation 5 to the G gamma gene. Proc Natl Acad Sci USA. 1984. doi: 10.1073/pnas.81.15.4894
Thein, S. Discovering the genetics underlying foetal haemoglobin production in adults. British Journal of Haematology. 2009. doi: 10.1111/j.1365-2141.2009.07650.x
Read more:
What is Hereditary Persistence of Fetal Hemoglobin? - News-Medical.net
- The therapeutic potential of stem cells - PubMed Central (PMC) - November 12th, 2024
- Stem Cell Therapy Market Is Projected To Achieve A Market Value Of USD 3.40 Bn. By 2030, Reflecting A Robus... - WhaTech - October 18th, 2024
- Doctor who provided ineffective stem cell therapies disciplined 6 years after investigation began - CBS Chicago - October 15th, 2024
- Study reveals the benefits and downside of fasting - Big Think - September 28th, 2024
- Tiny vesicles from umbilical cord blood may have therapeutic benefit - Parkinson's News Today - September 28th, 2024
- The Stem Cell Solution Review: Is This Program the Future of Anti-Aging and Recovery? - Enumclaw Courier-Herald - September 28th, 2024
- Cell and Gene Therapy Research To Benefit From New Stem Cell Collection Center - Technology Networks - September 25th, 2024
- Stem Cell Restore: A Full Review of Its Role in Promoting Regeneration and Vitality - Islands' Sounder - September 18th, 2024
- Is fasting good for you? A new study reveals some hidden risks and benefits of the practice - Business Insider India - August 31st, 2024
- Study reveals the benefits and downside of fasting - MIT News - August 27th, 2024
- Scilex Holding Company Announces the U.S. Patent and Trademark Office Will Be Issuing New ELYXYB® Patent Related to the Treatment of Acute Pain - August 22nd, 2024
- Oragenics Inc. Completes Spray Dry Drug Manufacturing and Intranasal Device Filling in Anticipation of Phase IIa Clinical Trial in Concussed Patients - August 22nd, 2024
- Orion Corporation: Managers’ transactions – Niclas Lindstedt - August 22nd, 2024
- PharmaTher’s Sairiyo Therapeutics Announces Independent Screening Identifying Cepharanthine’s Potential to Bind to Monkeypox (Mpox) Proteins - August 22nd, 2024
- BRIGHT GREEN EMBARKS ON MAJOR PARTNERSHIP WITH BENUVIA PHARMACEUTICALS. WILL SUPPLY PHARMA EXPERT WITH AMERICAN MADE RAW MATERIALS FROM ITS INDUSTRY... - August 22nd, 2024
- Eyenovia Announces Pricing of $5.14 Million Public Offering - August 22nd, 2024
- Firefly Neuroscience Forms Strategic Partnership with Neurology Consultants of Dallas (NCD) to Enhance Early Detection Efforts and Disease Management... - August 22nd, 2024
- Clearmind Medicine Granted U.S. Patent Approval for Binge Behavior Treatment - August 22nd, 2024
- SIGA Announces New Contract Awarded by U.S. Department of Defense for the Procurement of $9 Million of TPOXX® - August 22nd, 2024
- MDxHealth Reports Q2 and Half Year 2024 Results - August 22nd, 2024
- Bavarian Nordic Receives 440,000 Dose Contract to Supply Smallpox and Mpox Vaccines for Undisclosed European Country - August 22nd, 2024
- Brains Bioceutical Set to Achieve One of the World’s First CEP for Cannabidiol Certification with the European Directorate for the Quality of... - August 22nd, 2024
- Cytek® Biosciences Achieves ISO 13485 Certification at San Diego Reagent Manufacturing Facility - August 22nd, 2024
- Certara to Participate in Upcoming Investor Conferences - August 22nd, 2024
- Orion Corporation: Managers’ transactions – Satu Ahomäki - August 22nd, 2024
- Bavarian Nordic Announces First Half 2024 Results - August 22nd, 2024
- BioCryst to Present at Upcoming Investor Conferences - August 22nd, 2024
- Zymeworks Announces Participation in Upcoming Investor Conferences - August 22nd, 2024
- MediWound Reports Second Quarter 2024 Financial Results and Provides Company Update - August 14th, 2024
- Viracta Therapeutics Announces Positive Data from the Phase 2 NAVAL-1 Trial, Regulatory Progress, and Updated Nana-val Clinical Development Plan - August 14th, 2024
- Shock Top and Gator Athletics Partner to Introduce First-Ever Craft Beer Sponsorship of the Florida Athletic Department - August 14th, 2024
- IGM Biosciences Announces Second Quarter 2024 Financial Results and Provides Corporate Update - August 14th, 2024
- Achilles Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Updates - August 14th, 2024
- Neumora Therapeutics to Host Key Opinion Leader Roundtable to Discuss the Potential of Navacaprant in Neuropsychiatric Disorders - August 14th, 2024
- Evaxion Announces Business Update and Second Quarter 2024 Financial Results - August 14th, 2024
- Galera Announces Board Approval of Complete Liquidation and Dissolution - August 14th, 2024
- Outlook Therapeutics® Reports Financial Results for Third Quarter Fiscal Year 2024 and Provides Corporate Update - August 14th, 2024
- Viracta Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update - August 14th, 2024
- Omega Therapeutics Announces Jennifer Nelson, Ph.D., as Senior Vice President of Research - August 14th, 2024
- CorMedix Inc. Reports Second Quarter and Six Month 2024 Financial Results and Provides Business Update - August 14th, 2024
- Panavance Therapeutics Announces Foundational Publication of Misetionamide (GP-2250) in Ovarian Cancer in the Journal, Cancer Medicine - August 14th, 2024
- Abeona Therapeutics® Announces Appointment of Bernhardt Zeiher, MD, FCCP, FACP, and Eric Crombez, MD to its Board of Directors - August 14th, 2024
- Veralox Therapeutics Announces EMA Orphan Drug Designation for VLX-1005 - August 14th, 2024
- Verrica Pharmaceuticals Announces Positive Preliminary Topline Results from Part 2 of Phase 2 Clinical Study of VP-315, an Investigational Oncolytic... - August 14th, 2024
- Verrica Pharmaceuticals Reports Second Quarter 2024 Financial Results - August 14th, 2024
- Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons - August 14th, 2024
- Atsena Therapeutics Receives Rare Pediatric Disease Designation from the U.S. FDA for ATSN-201 Gene Therapy to Treat X-linked Retinoschisis - August 14th, 2024
- Aquestive Therapeutics Comments on Recent FDA Approval of Non-Injection-Based Epinephrine Product for the Treatment of Anaphylaxis and Reiterates... - August 14th, 2024
- What Is Stem Cell Therapy? How Does It Work? - ThePrint - August 6th, 2024
- New Study Shows Short-Term Benefits of Stem Cell Therapy for MS Patients, But Long-Term Efficacy Remains Unclear - Managed Healthcare Executive - July 26th, 2024
- Cord Blood Awareness Month: Advantages of cord blood banking, things to keep in mind - Moneycontrol - July 10th, 2024
- Neural Stem Cell Plasticity: Advantages in Therapy for the Injured Central Nervous System - Frontiers - June 28th, 2024
- Harnessing benefits of stem cells for heart regeneration | ASU News - ASU News Now - June 21st, 2024
- 'Didn't know this would be possible': Autistic teen's mom on stem cell therapy benefits - WZTV - May 6th, 2024
- John Cleese says he's been spending 17,000 annually on stem cell therapy to 'buy a few extra years' - Yahoo News UK - April 24th, 2024
- Promethera Bets Liver-Derived Stem Cells Will Offer Benefits In NASH - Scrip - April 24th, 2024
- Stem Cell Therapies: Is This The Future Of Wellness? - Grazia USA - April 20th, 2024
- Signal of Benefit for Stem Cell Therapy in Progressive MS - Medscape - March 7th, 2024
- The Controversies Surrounding Stem Cell Therapy for Autism - The Portugal News - February 24th, 2024
- Benefits of Stem Cell Therapy - News Channel 5 Nashville - February 7th, 2024
- What is Stem Cell Therapy & How It Helps Others - Publicist Paper - January 31st, 2024
- A guide to stem cell therapy in Thailand - Thaiger - January 4th, 2024
- Half of pediatric patients with aHUS benefit from Soliris after... - AHUS News - December 21st, 2023
- Real world analysis on the determinants of survival in primary ... - Nature.com - December 5th, 2023
- The Best Beauty Gifts According To People Who Really Know Skin Care - HuffPost - December 5th, 2023
- The Eyepopping Factory Construction Boom in the US - WOLF STREET - December 3rd, 2023
- Benefit of Neoadjuvant Therapy Illustrated During ESMO Congress ... - Targeted Oncology - December 1st, 2023
- Benefits Outweigh Risks as FDA Inspects CAR-T Cell Therapy ... - Curetoday.com - December 1st, 2023
- Review What Real Cavityn Customers Say About Benefits and Side ... - Seattle Weekly - December 1st, 2023
- 'There is a Scientific Fraud Epidemic' - Slashdot - Slashdot - December 1st, 2023
- 15 Best Hydrating Serums to Soothe Any Skin Type 2023 - Town & Country - December 1st, 2023
- Innovations in Cosmetic Dermatology: A Glimpse into the Future - APN News - December 1st, 2023
- FDA Probes New Cases of Cancer That May Stem From Cancer Cell ... - MedCity News - November 29th, 2023
- Use of plant stem cells in topical formulations on the rise - CosmeticsDesign.com USA - November 29th, 2023
- Stem cell-based treatment controls blood sugar in people with Type ... - EurekAlert - November 29th, 2023
- Biologics Market is projected to grow at a CAGR of 8.5% by 2034: Visiongain - Yahoo Finance - November 29th, 2023
- Scientists devise new technique that can pinpoint the causes and ... - EurekAlert - November 29th, 2023
- Global Advanced Therapy Medicinal Products Market is on the brink ... - PharmiWeb.com - November 29th, 2023
- Introducing Orgavalue - The 2023 EIT InnoStars Awards winner - EU-Startups - November 29th, 2023
- Episode 160: Euan Ashley discusses precision medicine and the ... - IHMC - November 29th, 2023
Recent Comments